Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin’s lymphoma: A systematic review and meta-analysis

Cardiovascular adverse events associated with cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and prednisone with or without rituximab ((R)-CDOP) in non-Hodgkin’s lymphoma: A systematic review and meta-analysis

Background: The (R)-CDOP combination regimen, based on pegylated liposomal doxorubicin, is increasingly used for elderly patients with non-Hodgkin’s lymphoma. However, the cardiotoxicity and efficacy of the (R)-CDOP regimen compared with conventional anthracyclines have not been demonstrated in the...

Full description

Bibliographic Details
Main Authors: Bin Lu, Longfei Shen, Ying Ma, Jia Qi, Yulin Li, Zhihao Wang, Lu Han, Ming Zhong
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Pharmacology
Subjects:
non-Hodgkin’s lymphoma
liposomes
(R)-CDOP combination regimen
cardiotoxicity
adverse cardiovascular events
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.1060668/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.1060668/full

Similar Items